


PRODUCT: AT-7519 hydrochloride**ALTERNATE NAME:** N-(4-PiperidinyI)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide hydrochloride**CATALOG #:** 2816-5, 25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₁₆H₁₈Cl₃N₅O₂**MOLECULAR WEIGHT:** 418.71**CAS NUMBER:** 902135-91-5**APPEARANCE:** White solid**SOLUBILITY:** DMSO**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20 °C. Protect from light and moisture

DESCRIPTION: AT-7519 is a potent CDK inhibitor with potential antineoplastic activity. AT-7519 displays potent antiproliferative activity (40-940 nM) in a panel of human tumor cell lines, and the mechanism of action is shown to be consistent with the inhibition of CDK1 and CDK2 in solid tumor cell lines. AT-7519 causes cell cycle arrest followed by apoptosis in human tumor cells and inhibits tumor growth in human tumor xenograft models.

REFERENCES: Squires, M.S., *et al.* (2009). *Mol. Cancer Ther.* 8,324-332.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

Alsterpaullone (Cat. No. 1897-1,5)
 Butyrolactone I (Cat. No. 1690-200)
 Doramapimod (Cat. No. 1954-5, 25)
 Flavopiridol (Cat. No. 2090-1, 5)
 10Z-Hymenialdisine (Cat. No. 2212-250, 1000)
 Kenpaullone (Cat. No. 1904-1)
 PD1834352 (CI-1040) (Cat. No. 1585-1,5,25)
 EZSolution™ PD184352 (Cat. No. 1871-1)
 PD325901 (Cat. No. 1643-2, 5, 25)
 PD98059 (Cat. No. 1666-5)
 EZSolution™ PD98059 (Cat. No. 1783-5)
 (R)-Perharidine-1 (Cat. No. 2615-1,5)
 RO-3306 (Cat. No. 2039-1,5)
 Roscovitine (Cat. No. 1950-1,5)
 SB 203580 (Cat. No. 1712-1, 5)
 EZSolution™ SB203580 (1786-1)
 Sorafenib (Cat. No. 1594-25, 100)
 TG003 (Cat. No. 1905-5, 25)
 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
 U0126 (Cat. No. 1668-5)
 VX-702 (Cat. No. 1598-1,5)

USAGE: FOR RESEARCH CH USE ONLY! Not to be used in humans